



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231, on

By David L. Lane 6/18/96

H7
CJL
7/3/96
PATENT

Attorney Docket No. 014137-005840

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
GREY, et al.)
Serial No.: 08/349,177)
Filed: December 2, 1994)
For: HLA-A2.1 BINDING PEPTIDES)
AND THEIR USES)

)

) Examiner: Schwadron
)
Art Unit: 1816

RESPONSE TO RECEIVED
COMMUNICATION JUN 20 1996
GROUP 1800

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

This paper is in response to the Communication dated June 13, 1996 indicating that the response mailed March 7, 1996 is not responsive to the restriction requirement mailed February 6, 1996. As noted in the communication, the peptide species elected in the March 7 response (KMVELVHFL) is not within the scope of the elected claims. Applicants hereby maintain the election with traverse of Group A (a peptide of 9 residues) and elect species YIFATCLGL. This peptide meets the limitations of claim 1 and is disclosed on page 29 of the present application.

Applicants again respectfully submit that search and examination of the entire application can be made without serious burden to the Examiner and, therefore, the claims should be examined together. As noted previously, the claims are all directed to peptides

that bear an HLA A2.1 binding motif. Applicants respectfully that piecemeal examination of the claims in the application would place an undue burden on applicants and the PTO. If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (415) 576-0200.

Respectfully submitted,

By 

Kevin L. Bastian
Reg. No. 34,774

Townsend and Townsend and Crew
Two Embarcadero, 8th Floor
San Francisco, California 94111
Telephone: (415) 576-0200